Blood Test Could Predict Metastasis Risk in Melanoma
With the rising incidence of melanoma, there is a great need for a more cost effective method of surveillance for disease recurrence. Yale University scientists have identified a set of plasma biomarkers that could predict the risk of metastasis among patients with melanoma.
Patients with melanoma are typically subjected to a combination of imaging tests, blood tests and physical examinations, but there is no clear consensus on how often these tests should occur or how reliable they are.
Lead author Harriet Kluger, M.D., associate professor of medicine at Yale University School of Medicine, said "Our current method of surveillance includes periodic imaging, which creates huge societal costs."
Kluger and colleagues have published their findings in Clinical Cancer Research, a journal of the American Association for Cancer Research.
Kluger and colleagues employed ELISA assays to measure proteins in plasma of 216 individuals, including 108 patients with metastatic melanoma and 108 patients with stage 1 or 2 disease.
They identified seven plasma biomarkers: CEACAM, ICAM-1, osteopontin, MIA, GDF-15, TIMP-1 and S100B. All of these biomarkers were higher in patients with metastatic melanoma than patients with early-stage disease.
About 81% of the stage I/II patients in the training set had no marker elevation, whereas 69% of the stage IV patients had elevation of at least one marker (P
Researchers calculated that the area under the curve, a measure of the test's reliability, was 0.898. Area under the curve calculations rate from .5 to 1, with 1 being optimal and .5 being useless.
"This finding will need to be confirmed prospectively before it is used in the clinic, but it shows that such testing is possible," said Kluger.
If the finding is confirmed, then imaging could be used in selected patients rather than all patients under surveillance, reducing healthcare costs to society and reducing radiation to individual patients.